Morgan Stanley’s IO Biotech IOBT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-206,215
| Closed | -$12.1K | – | 8499 |
|
|
2026
Q1 | $12.1K | Sell |
206,215
-332,967
| -62% | -$114K | ﹤0.01% | 6895 |
|
|
2025
Q4 | $328K | Sell |
539,182
-129,220
| -19% | -$96K | ﹤0.01% | 5720 |
|
|
2025
Q3 | $243K | Buy |
668,402
+14,724
| +2% | +$25.4K | ﹤0.01% | 5812 |
|
|
2025
Q2 | $909K | Sell |
653,678
-135,783
| -17% | -$155K | ﹤0.01% | 5150 |
|
|
2025
Q1 | $861K | Sell |
789,461
-69,714
| -8% | -$65.8K | ﹤0.01% | 5075 |
|
|
2024
Q4 | $790K | Sell |
859,175
-1,342,910
| -61% | -$1.34M | ﹤0.01% | 5208 |
|
|
2024
Q3 | $2.31M | Buy |
2,202,085
+229,742
| +12% | +$289K | ﹤0.01% | 4543 |
|
|
2024
Q2 | $2.31M | Sell |
1,972,343
-224,891
| -10% | -$314K | ﹤0.01% | 4467 |
|
|
2024
Q1 | $3.8M | Sell |
2,197,234
-2,366,130
| -52% | -$4.11M | ﹤0.01% | 4135 |
|
|
2023
Q4 | $8.58M | Buy |
4,563,364
+4,494,551
| +6,532% | +$5.36M | ﹤0.01% | 4037 |
|
|
2023
Q3 | $97K | Sell |
68,813
-135
| -0.2% | -$237 | ﹤0.01% | 5906 |
|
|
2023
Q2 | $135K | Buy |
68,948
+25,753
| +60% | +$50.3K | ﹤0.01% | 5812 |
|
|
2023
Q1 | $81K | Buy |
43,195
+14,135
| +49% | +$35.2K | ﹤0.01% | 6096 |
|
|
2022
Q4 | $66.8K | Buy |
29,060
+7,000
| +32% | +$18.5K | ﹤0.01% | 6159 |
|
|
2022
Q3 | $60K | Sell |
22,060
-2,049
| -8% | -$7.6K | ﹤0.01% | 6326 |
|
|
2022
Q2 | $113K | Buy |
24,109
+7,622
| +46% | +$46.7K | ﹤0.01% | 6210 |
|
|
2022
Q1 | $87K | Buy |
16,487
+7,529
| +84% | +$49.8K | ﹤0.01% | 6396 |
|
|
2021
Q4 | $57K | Buy |
+8,958
| New | +$86.5K | ﹤0.01% | 6749 |
|
Morgan Stanley's IOBT Position: Q2 2026 in Review
Morgan Stanley sold out of IO Biotech (IOBT) in Q2 2026, closing a stake of 206,215 shares — an estimated $12.1K sold.
Morgan Stanley first reported a position in IOBT in Q4 2021 and held it in 18 quarters. The position peaked at $8.58M in Q4 2023. 0 funds tracked by Wall St. Rank hold IOBT as of Q2 2026.
- Morgan Stanley reported no remaining IO Biotech position as of Q2 2026 after selling out during the quarter.
- Morgan Stanley sold 206,215 IO Biotech shares in Q2 2026, an estimated $12.1K.
- Morgan Stanley first reported a position in IO Biotech in Q4 2021 and held it in 18 quarters.
- Morgan Stanley's IO Biotech position peaked at $8.58M in Q4 2023.
- 0 funds tracked by Wall St. Rank held IO Biotech as of Q2 2026.
Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.